product name Cefoselis Sulfate
Description: Cefoselis (also known as FK 037 Sulfate) is a widely used beta-lactam antibiotic. Cefoselis inhibits GABA-induced currents in a concentration-dependent manner with IC50 of 185 mM. Cefoselis possesses a superior antistaphylococcal activity on MSSA isolates to both other compounds being however equal active to Cefepime and Cefpirome on multiresistant enterobacteriaceae. Cefoselis is dose-dependently appeared in brain extracellular fluid in proportion to its blood level. Cefoselis, a new parenteral cephalosporin, is active against clinical isolates of both gram-positive and gram-negative aerobic bacteria.
References: Br J Pharmacol. 2002 Jan;135(2):427-32; J Neural Transm (Vienna). 2004 Dec;111(12):1523-35.
620.64
Formula
C19H22N8O6S2.H2SO4
CAS No.
122841-12-7
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 3 mg/mL (4.8 mM)
Water: 5 mg/mL (8.0 mM)
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
FK 037 Sulfate
other peoduct :
| In Vitro |
In vitro activity: Cefoselis inhibits GABA-induced currents in a concentration-dependent manner with IC50 of 185 mM. Cefoselis possesses a superior antistaphylococcal activity on MSSA isolates to both other compounds being however equal active to Cefepime and Cefpirome on multiresistant enterobacteriaceae. Cefoselis is dose-dependently appeared in brain extracellular fluid in proportion to its blood level. Cefoselis, a new parenteral cephalosporin, is active against clinical isolates of both gram-positive and gram-negative aerobic bacteria. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Cefoselis elicits a massive elevation of extracellular glutamate concentration in normal rats. Cefoselis (50 mg/animal)-induced convulsions are prevented by pretreatment with 5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (MK-801), diazepam and phenobarbital (ED(50) values (mg/kg) of 0.78, 1.59 and 33.0, respectively), but not by carbamazepine or phenytoin. |
| Animal model | |
| Formulation & Dosage | |
| References | Br J Pharmacol. 2002 Jan;135(2):427-32; J Neural Transm (Vienna). 2004 Dec;111(12):1523-35. |
